Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
- Written by PR Newswire
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMMER-UP-SWITCH) evaluating ecnoglutide versus...














